This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| World Health Organization Uppsala Monitoring Centre | |
|---|---|
| Name | Uppsala Monitoring Centre |
| Formation | 1978 |
| Headquarters | Uppsala, Sweden |
World Health Organization Uppsala Monitoring Centre
The World Health Organization Uppsala Monitoring Centre is an international pharmacovigilance centre located in Uppsala, Sweden, affiliated with the World Health Organization Programme for International Drug Monitoring and collaborating with agencies such as the European Medicines Agency, Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency, and national centres in countries like India, Brazil, South Africa, Japan, United States, Germany, France, China, Australia.
The Uppsala Monitoring Centre was established in 1978 following decisions by the World Health Organization and consultations among experts from the United Kingdom, Sweden, Netherlands, Denmark, Norway, Finland, Italy, Spain, and Belgium to support the WHO Programme for International Drug Monitoring. Early collaborations included agencies such as the Centers for Disease Control and Prevention and the Council of Europe, while landmark events like meetings at the Karolinska Institute and conferences in Geneva shaped its mandate. During the 1980s and 1990s the Centre expanded activities through partnerships with the European Commission, World Bank, United Nations, UNICEF, World Trade Organization, and academic institutions including Uppsala University, Harvard University, Oxford University, Cambridge University, Johns Hopkins University, and Karolinska Institutet, reflecting growing global attention after crises such as the Thalidomide legacy and post-marketing safety issues handled by regulatory bodies like the Food and Drug Administration and Medicines and Healthcare products Regulatory Agency.
Governance of the Centre aligns with the World Health Organization structures and is overseen by member state representatives including delegates from the European Union, African Union, Association of Southeast Asian Nations, Organization of American States, and Gulf Cooperation Council. Executive leadership liaises with scientific committees, advisory boards, and partners such as the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Council for International Organizations of Medical Sciences, World Medical Association, International Society of Pharmacovigilance, and national regulatory authorities like the Swissmedic and Pharmaceuticals and Medical Devices Agency of Japan. Administrative offices coordinate with funding and oversight entities including the Swedish International Development Cooperation Agency, European Commission Directorate-General for Health and Food Safety, Bill & Melinda Gates Foundation, Wellcome Trust, Global Fund to Fight AIDS, Tuberculosis and Malaria, and bilateral donors.
The Centre conducts signal detection, benefit–risk assessment, and adverse event monitoring supporting programmes run by European Medicines Agency, Food and Drug Administration, Health Canada, Therapeutic Goods Administration, Medicines and Healthcare products Regulatory Agency, and ministries of health in India, Nigeria, Kenya, Brazil, Russia, Mexico, Indonesia, and Philippines. It contributes to pharmacovigilance during public health responses involving WHO campaigns such as immunization drives with Gavi, the Vaccine Alliance, responses to pandemics coordinated with World Health Organization emergency programmes, and collaboration with the Centers for Disease Control and Prevention during outbreaks like Ebola virus epidemic in West Africa and influenza events involving Pandemic influenza A (H1N1) 2009. The Centre supports regulatory decisions about medicines from manufacturers including Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Sanofi, Novartis, Roche, Merck & Co., and Bristol Myers Squibb by providing data analysis for safety communications and risk minimization measures.
The Centre maintains global databases and tools such as VigiBase, VigiFlow, and VigiAccess used by national centres and organizations including the European Medicines Agency, Food and Drug Administration, Health Canada, World Health Organization, and academic partners like Karolinska Institutet, Uppsala University, Harvard Medical School, London School of Hygiene & Tropical Medicine, and University of Oxford. VigiBase aggregates individual case safety reports from member countries including United States, United Kingdom, Japan, Germany, France, Brazil, India, China, South Africa, and Australia to enable signal detection methods comparable to techniques used by institutions such as European Centre for Disease Prevention and Control, National Institutes of Health, and Centers for Disease Control and Prevention. Analytical tools incorporate algorithms influenced by methods from the Cochrane Collaboration, Institute of Medicine, United Nations Educational, Scientific and Cultural Organization, and collaborations with technology companies and research groups at Massachusetts Institute of Technology and ETH Zurich.
The Uppsala Monitoring Centre runs research programmes and training with academic and international partners including Uppsala University, Karolinska Institutet, University of Cape Town, University of São Paulo, National Institutes of Health, Wellcome Trust, Bill & Melinda Gates Foundation, European Medicines Agency, Food and Drug Administration, WHO regional offices in WHO Regional Office for Africa, WHO Regional Office for South-East Asia, and institutions such as London School of Hygiene & Tropical Medicine and Johns Hopkins Bloomberg School of Public Health. Capacity building initiatives support national pharmacovigilance centres in Uganda, Tanzania, Ghana, Sri Lanka, Nepal, Bangladesh, Vietnam, Philippines, and Cambodia through workshops, online courses, and collaboration with professional societies like the International Society of Pharmacovigilance and World Medical Association.
The Centre partners with international organizations and stakeholders including the World Health Organization, European Medicines Agency, Food and Drug Administration, Health Canada, Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation, Wellcome Trust, United Nations Children's Fund, World Bank, World Trade Organization, and national regulatory agencies in Japan, China, Brazil, South Africa, India, Russia, Germany, France, United Kingdom to influence policies on medicine safety, vaccine surveillance, and public health interventions. Its datasets and analyses have informed regulatory actions by agencies like the European Commission, Pharmaceuticals and Medical Devices Agency, Swissmedic, Therapeutic Goods Administration, and legal frameworks influenced by international fora including the United Nations and World Health Assembly. The Centre’s global role is cited in collaborations with research funders such as the National Institutes of Health, European Research Council, Horizon 2020, Wellcome Trust, and multilateral initiatives including the Global Fund to Fight AIDS, Tuberculosis and Malaria.